Answers are grounded in this paper and cite their sources.
Investigates how aging affects anti-tumor immunity from radiation therapy, suggesting adjustments for better outcomes.
Radiotherapy (RT) has evolved from a purely cytotoxic treatment into a potent immune modulator capable of inducing systemic anti-tumor responses. High-dose precision approaches such as stereotactic body radiotherapy or stereotactic radiosurgery can trigger immunogenic cell death, enhance antigen presentation, and promote tumor-specific T-cell priming. However, the magnitude and quality of these radiation-induced immune effects depend critically on the biological age of the host immune system. Immunosenescence—defined by the gradual decline and remodeling of immune competence with age—profoundly alters both innate and adaptive immunity. The aged immune landscape is characterized by reduced responsiveness, chronic low-grade inflammation, and impaired coordination between immune effector cells. In this context, RT may not elicit the same immunogenic signals observed in younger patients. Instead, aging-associated immune alterations can dampen the anti-tumor potential of radiation or shift the balance toward prolonged inflammation and immune dysregulation. These effects highlight the need to consider immune aging as a key determinant of therapeutic response. Understanding how immunosenescence modulates radiation-induced immunity is essential for developing age-informed and immune-adaptive RT strategies. Integrating biomarkers of immune aging into treatment planning could enable truly personalized immuno-oncology approaches—optimizing efficacy, minimizing toxicity, and improving outcomes in older patients with cancer.
No takes yet. Share an insight, caveat, or question.
Arnold et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: